Form 8-K - Current report:
SEC Accession No. 0001759425-24-000037
Filing Date
2024-11-12
Accepted
2024-11-12 08:04:41
Documents
14
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mirm-20241112.htm   iXBRL 8-K 27512
2 EX-99.1 mirm-20241112xexx991.htm EX-99.1 118294
  Complete submission text file 0001759425-24-000037.txt   282705

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mirm-20241112.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mirm-20241112_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mirm-20241112_pre.xml EX-101.PRE 12508
16 EXTRACTED XBRL INSTANCE DOCUMENT mirm-20241112_htm.xml XML 2874
Mailing Address 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY CA 94404
Business Address 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)

EIN.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38981 | Film No.: 241443536
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)